Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 77Multiple Myeloma 40Lymphoma, Large B-Cell, Diffuse 40Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma 37Lymphoma, Non-Hodgkin 27Leukemia 26Leukemia, Lymphocytic, Chronic, B-Cell 18Burkitt Lymphoma 18Recurrence 17Lymphoma, Mantle-Cell 17Lymphoma, Follicular 17Neoplasms, Plasma Cell 16Lymphoma, B-Cell 16Leukemia, Myeloid, Acute 16Neuroblastoma 12Hodgkin Disease 12Lymphoma, Large-Cell, Immunoblastic 11Myelodysplastic Syndromes 9Lymphoma, T-Cell, Peripheral 9Lymphoma, B-Cell, Marginal Zone 9Inflammatory Breast Neoplasms 9Triple Negative Breast Neoplasms 8Sarcoma 8Ovarian Neoplasms 8Immunoblastic Lymphadenopathy 7Neoplasm Metastasis 6Melanoma 6Leukemia, Myeloid, Chronic-Phase 6Hematologic Neoplasms 6

Interventions

fludarabine 1Sensitivity and Specificity 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Leukemia, Prolymphocytic, T-Cell × Cyclophosphamide × Clear all
NCT04823091 2022-03-16

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 1 Unknown
24 enrolled
LymphoidOther hematologic neoplasm

Leukemia, T-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡